- Home
- NGNE vs ACCO Comparison
NGNE vs ACCO Comparison
Compare NGNE & ACCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- ACCO
- Stock Information
- Founded
- NGNE 2003
- ACCO 1893
- Country
- NGNE United States
- ACCO United States
- Employees
- NGNE N/A
- ACCO N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- ACCO Publishing
- Sector
- NGNE Health Care
- ACCO Consumer Discretionary
- Exchange
- NGNE Nasdaq
- ACCO Nasdaq
- Market Cap
- NGNE 325.3M
- ACCO 353.3M
- IPO Year
- NGNE N/A
- ACCO N/A
- Fundamental
- Price
- NGNE $18.48
- ACCO $4.00
- Analyst Decision
- NGNE Strong Buy
- ACCO Buy
- Analyst Count
- NGNE 7
- ACCO 1
- Target Price
- NGNE $41.86
- ACCO $6.00
- AVG Volume (30 Days)
- NGNE 110.1K
- ACCO 530.2K
- Earning Date
- NGNE 08-11-2025
- ACCO 07-31-2025
- Dividend Yield
- NGNE N/A
- ACCO 7.46%
- EPS Growth
- NGNE N/A
- ACCO N/A
- EPS
- NGNE N/A
- ACCO 0.49
- Revenue
- NGNE N/A
- ACCO $1,581,200,000.00
- Revenue This Year
- NGNE N/A
- ACCO N/A
- Revenue Next Year
- NGNE N/A
- ACCO $2.11
- P/E Ratio
- NGNE N/A
- ACCO $8.21
- Revenue Growth
- NGNE N/A
- ACCO N/A
- 52 Week Low
- NGNE $6.88
- ACCO $3.32
- 52 Week High
- NGNE $74.49
- ACCO $6.44
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- ACCO 59.22
- Support Level
- NGNE $19.59
- ACCO $3.90
- Resistance Level
- NGNE $20.46
- ACCO $4.01
- Average True Range (ATR)
- NGNE 1.23
- ACCO 0.10
- MACD
- NGNE -0.20
- ACCO 0.01
- Stochastic Oscillator
- NGNE 13.37
- ACCO 79.91
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About ACCO Acco Brands Corporation
ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.